Vous êtes ici : Accueil > Espace Médecin > La revue de Presse > Journal of Hepatology

Mise jour le : 20-09-2017

Les derniers abstracts de la revue Journal of Hepatology :

    Date de mise en ligne : Lundi 18 septembre 2017
    Gamal Esmat, Tamer Elbaz, Maissa El Raziky, Asmaa Gomaa, Mahmoud Abouelkhair, Hadeel Gamal El Deen, Aliaa Sabry, Mohamed Ashour, Naglaa Allam, Mohamed Abdel-Hamid, Ola Nada, Sherine Helmy, Hanaa Abdel-Maguid, Richard Colonno, Nathaniel Brown, Eric Ruby, Pamela Vig, Imam Waked
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis c genotype-4
    Hepatitis C virus (HCV) infection is a major global health problem, affecting 70 million to 100 million persons worldwide [1], and accounts for around 360,000 annual deaths due to decompensated cirrhosis and hepatocellular carcinoma [2]. HCV-genotype-4 (GT4) accounts for 10%-15% of chronic HCV infection worldwide, affecting 12 million to 15 million patients, mostly in limited resource countries in Africa and the Middle East. Egypt has the highest prevalence of chronic HCV worldwide; with the predominant genotype being genotype-4 in more than 90% of affected patients [3].

    Date de mise en ligne : Vendredi 15 septembre 2017
    Tim F. Greten, Bruno Sangro
    Targets for immunotherapy of liver cancer
    Drug development in HCC has been characterized in the past by many failures. Despite good rationales and promising phase II data, many phase III trials failed. Immunotherapy represents an alternate treatment approach and has been successful in many different types of cancer. Being an inflammation induced cancer HCC represents a very interesting target for immune based approaches and indeed early results from clinical trials testing immune checkpoint inhibitors are not only promising but have already led to evaluation of such in a phase III setting.

    Date de mise en ligne : Vendredi 15 septembre 2017
    Xavier Adhoute, Guillaume Pénaranda, Floriane Sellier, Jean-Luc Raoul
    Response to “the flexible therapeutic approach to the BCLC B stage”: time for scoring systems?
    We have read with interest the review by Galle et al concerning the therapeutic strategy in intermediate stage hepatocellular carcinoma (HCC)[1]. The heterogeneity of this group is highlighted, whereas only transarterial chemoembolization (TACE) is recommended in the guidelines. However, some (Barcelona Clinic Liver Cancer) BCLC B patients may not benefit from TACE. Thus, in this review other therapeutic approaches are discussed, based on a very exhaustive review of the literature, from transplantation to the most recent systemic treatments such as immunotherapy.

    Date de mise en ligne : Vendredi 15 septembre 2017
    Friedrich Foerster, Marcus-Alexander Wörns, Peter Robert Galle
    REPLY TO LETTER TO THE EDITOR - Response to “the flexible therapeutic approach to the BCLC B stage”: time for scoring systems?
    We have read with great interest the commentary “Response to “the flexible therapeutic approach to the BCLC B stage”: time for scoring systems?“ by Adhoute et al. on our recent review about the treatment of intermediate stage HCC (“The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy”[1]).

    Date de mise en ligne : Mercredi 13 septembre 2017
    Stacey Prenner, Laura Kulik
    Reply to “Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma”
    To the Editor,

    Date de mise en ligne : Mercredi 13 septembre 2017
    Dominique Thabut, Arnaud Pauwels, Nicolas Carbonell, Andre Jean Remy, Pierre Nahon, Xavier Causse, Jean-Paul Cervoni, Jean-François Cadranel, Isabelle Archambeaud, Slim Bramli, Florent Ehrhard, Philippe Ah-Soune, Florian Rostain, Alexandre Pariente, Julien Vergniol, Jean-Pierre Dupuychaffray, Anne-Laure Pelletier, Florence Skinazi, Anne Guillygomarc'h, René-Louis Vitte, Jean Henrion, Stéphanie Combet, Marika Rudler, Christophe Bureau, des Hépato-Gastroentérologues des Hôpitaux Généraux (ANGH)
    Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a large multicentre audit with real-life results
    Gastrointestinal bleeding related to portal hypertension (PHT) is a frequent and severe complication of cirrhosis and has a high mortality rate. The introduction of new treatment strategies has greatly reduced mortality over the past 20 years [1]. The most important step occurs during the early placement of a covered transjugular intra-hepatic porto-systemic shunt (TIPS) (i.e., within 72 hours at most after control of bleeding) in high-risk patients. The first study in which this strategy was tested was published 5 years ago and showed a reduction of rebleeding and, more importantly, a decrease in mortality in high-risk patients (defined as Child-Pugh C or Child-Pugh B with active bleeding at endoscopy) [2].

    Date de mise en ligne : Mardi 12 septembre 2017
    Ao Huang, Xin Zhao, Xin-Rong Yang, Fu-Qiang Li, Xin-Lan Zhou, Kui Wu, Xin Zhang, Qi-Man Sun, Ya Cao, Hong-Mei Zhu, Xiang-Dong Wang, Huan-Ming Yang, Jian Wang, Zhao-You Tang, Yong Hou, Jia Fan, Jian Zhou
    Corrigendum to “Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma” [J Hepatol 67 (2017) 293–301]
    The corresponding authors’ addresses were not listed correctly in their contact order for this article. The corresponding authors’ addresses were corrected according to their contact order.

    Date de mise en ligne : Vendredi 08 septembre 2017
    Jean-François Dufour
    In Memoriam: Professor Jürg Reichen (1946–2017)
    Professor Jürg Reichen passed away unexpectedly on 25 July 2017 at the age of 71, with an abruptness befitting his character. Professor Reichen was not someone to accept being diminished by any disease. He was a driving force and a major figure in hepatology over the last 30years. He was born in January 1946 in the canton of Bern, Switzerland. He graduated from the University of Bern Medical School in 1971 and joined the Institute of Clinical Pharmacology, which was founded a few years before by his mentor Professor Rudolf Preisig.

    Date de mise en ligne : Vendredi 08 septembre 2017
    Rajeshwar P. Mookerjee, Gautam Mehta, Vairappan Balasubramaniyan, Fatma El Zahraa Mohamed, Nathan Davies, Vikram Sharma, Yasuko Iwakiri, Rajiv Jalan
    Corrigendum to “Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension” [J Hepatol 62 (2015) 325–331]
    Correction to the Title Page and Author affiliation for Dr Fatma El Zahraa Mohamed.

    Date de mise en ligne : Jeudi 07 septembre 2017
    Stefano Fangazio, Deborah Camatta, Margherita Tran Minh, Elisa Ceriani, Rosalba Minisini, Mario Pirisi
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma
    We read with interest the paper by Prenner et al., showing that in the presence of active hepatocellular carcinoma (HCC) the chances of successful hepatitis C virus (HCV) therapy with direct-acting antivirals (DAA) are decreased.[1] In our opinion, these data may have implications for the debate surrounding the surprisingly high detection rates of either de novo or recurrent HCC early after treatment of chronic hepatitis C with DAA, recently reported and commented in the Journal.[2–4] In fact, both the very existence of this phenomenon and its putative explanation (sudden loss of host immune control in the liver following clearance of the virus) have been questioned.

    Date de mise en ligne : Jeudi 07 septembre 2017
    Roger Williams
    In Memoriam: Rudolf Preisig (1929–2017), a major contributor to international hepatology
    Rudi Preisig was one of a small band of truly academic clinicians who helped to forge the development of hepatology as a specialty in Europe during the 1960s–1970s. After qualifying at the University of Bern Medical School, Rudi decided he wanted to obtain more exacting training in liver disease at a top centre in the United States, where he could also gain research experience. This was to be in the laboratory of Professor Stanley Bradley, of liver blood flow fame, then Chairman of Medicine at the Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York.

    Date de mise en ligne : Mardi 05 septembre 2017
    Stanley M. Lemon, Jördis J. Ott, Pierre Van Damme, Daniel Shouval
    Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention
    Hepatitis A virus (HAV) infection is an ancient disease and likely to have afflicted mankind since humans first began to live in groups large enough to sustain transmission of the causative agent, HAV. In reviewing what was known as 'catarrhal jaundice' in 1912, Cockayne noted descriptions of epidemic jaundice extending back to antiquity1. The infectious nature of the disease was proven several decades later in deliberate human transmission studies2. Such experiments led to a clear distinction between hepatitis A ('infectious hepatitis') and hepatitis B ('homologous serum jaundice') and recognition of the lack of cross immunity between these two forms of transmissible hepatitis as early as 19453.

    Date de mise en ligne : Mardi 05 septembre 2017
    Xiaolong Qi, Fuquan Liu, Zhiwei Li, Sizhe Chen, Yanna Liu, Yongping Yang, Jinlin Hou
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis
    We read with great interest the paper “Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma”, in which Iranmanesh et al. proposed a computed tomography (CT)-based model to predict invasive hepatic venous pressure gradient (HVPG) [1]. The noninvasive CT-based model combining the liver/spleen volume ratio with the peri-hepatic ascites demonstrated a high accuracy in predicting HVPG > 10 mmHg (area under the receiver operating characteristic curve (AUC): 0.911 [0.847–0.975]), with sensitivity, specificity, and positive and negative predictive values of 92%, 79%, 91%, and 81%, respectively [1].

    Date de mise en ligne : Mardi 05 septembre 2017
    Hui Ling Ko, Tze Hau Lam, Huijin Ng, Jiaying Toh, Liang Wei Wang, Ee Chee Ren
    Identification of Slug and Sox7 as transcriptional repressors binding to the Hepatitis B Virus Core Promoter
    Hepatitis B virus (HBV) affects 240 million chronic carriers globally and is linked to ∼800,000 deaths annually from complications including cirrhosis and liver cancer [1]. Hepatocytes are the primary site for HBV replication, as viral entry is facilitated by sodium taurocholate cotransporting polypeptide (NTCP) [2]. However, the efficiency of NTCP-mediated viral entry into cells has been shown to be highly variable, even after artificial overexpression [3]. Interestingly non-liver cells engineered to express NTCP cannot support HBV infection and subsequent replication [4].

    Date de mise en ligne : Mardi 05 septembre 2017
    Xiaozhan Wang, Wenzhe Mao, Chun Fang, Song Tian, Xueyong Zhu, Ling Yang, Zan Huang, Hongliang Li
    Dusp14 protects against hepatic ischemia-reperfusion injury via Tak1 suppression
    Liver ischemia-reperfusion (I/R) injury is a primary factor of liver dysfunction, liver non-function, and mortality after liver surgery [1]. Extensive cell death and an excessive inflammatory response are two prominent aspects of this pathology. Hepatocyte death is rapidly induced due to oxygen interruption, glycogen consumption, and ATP deletion under ischemic conditions [2], and reactive oxygen species (ROS) production post-reperfusion stimulates inflammatory responses, including macrophage and neutrophil infiltration and cytokine production [3].

    Date de mise en ligne : Mardi 05 septembre 2017
    Pouya Iranmanesh, Christian Toso
    Reply to the Letter to the Editor by Qi et al. entitled “Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis”
    We thank Qi et al.[1] for their interest in our study entitled “Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma”[2]. This study proposes a non-invasive computed tomography (CT)-based model predicting the level of hepatic venous pressure gradient in patients with cirrhosis, using the formula:

    Date de mise en ligne : Mardi 05 septembre 2017
    George N. Ioannou, Pamela K. Green, Kristin Berry
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma
    Kaplan-Meier curves of survival free of HCC by cirrhosis and SVR status after DAA-only antiviral treatment: SVR is associated with a reduction in HCC risk both among patients with cirrhosis and those without cirrhosis.

    Date de mise en ligne : Lundi 04 septembre 2017
    Aimilia Karampatou, Xue Han, Loreta A. Kondili, Gloria Taliani, Alessia Ciancio, Filomena Morisco, Rosina Maria Critelli, Enrica Baraldi, Veronica Bernabucci, Giulia Troshina, Maria Guarino, Simonetta Tagliavini, Federica D'Ambrosio, Laura Bristot, Laura Turco, Stefano Rosato, Stefano Vella, Tommaso Trenti, Isabella Neri, Antonio La Marca, Shivaji Manthena, Andrea S. Goldstein, Savino Bruno, Yanjun Bao, Yuri Sanchez Gonzalez, Erica Villa, PITER framework investigators
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection
    Menopause represents a critical event in a woman’s life. Rapid loss of estrogen and of its protective anti-inflammatory effects leads to a series of biological events characterized by a shift from a non-inflamed to an inflammation-prone environment. These changes translate into systemic symptoms, such as joint pain, metabolic syndrome, and others. In women infected with hepatitis C virus (HCV), menopause has direct effects on the liver, which include faster progression of fibrosis and marked resistance to IFN-based antiviral therapy [1–3].

    Date de mise en ligne : Vendredi 01 septembre 2017
    Rui Huang, Yong Liu, Jian Wang, Juan Xia, Xiaomin Yan, Chao Wu
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
    To the Editor:

    Date de mise en ligne : Vendredi 01 septembre 2017
    Han Wu, Han Zhang, Lun-Yang Hu, Tian-Yi Zhang, Yi-Jie Zheng, Feng Shen, Tian Yang
    Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?

    Date de mise en ligne : Vendredi 01 septembre 2017
    P. Kron, A. Schlegel, L. Mancina, P.-A. Clavien, P. Dutkowski
    Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans
    Fatty liver diseases have emerged as a new major health problem worldwide, leading to a continuous increase of available donor livers containing fat [1]. However, since fatty liver grafts were identified as independent risk factor for graft failure after implantation [2], many programs are very reluctant to use them [3]. Although microsteatosis is of lesser clinical relevance compared to macrosteatosis, histological assessment of the degree and type of steatosis at the time of organ allocation remains variable [4,5].

    Date de mise en ligne : Vendredi 01 septembre 2017
    Sven H. Loosen, Christoph Roderburg, Tom Luedde
    Reply to: “Is osteopontin a promising prognostic biomarker for cholangiocarcinoma?”
    We thank Wu and colleagues for their interest in our study and appreciate the chance to reply to their statements:

    Date de mise en ligne : Vendredi 01 septembre 2017
    Terry Cheuk-Fung Yip, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
    Reply to: “Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance”
    To the Editor:

    Date de mise en ligne : Vendredi 01 septembre 2017
    Chiara Mazzarelli, Mary D. Cannon, Luca S. Belli, Kosh Agarwal
    Direct-acting antiviral therapy in patients with hepatocellular cancer: the timing of treatment is everything
    We read with interest the recent publication by Beste and colleagues, which focused on the negative impact of hepatocellular cancer (HCC) on SVR in a large cohort of patients treated with direct-acting antiviral agents (DAA) in the Veteran Affairs (VA) program1. The authors report that patients who had undergone liver transplantation for HCC (HCC/LT) had a rate of SVR similar to patients without HCC (no-HCC), with a lower rate of SVR seen in those patients with HCC who did not undergo LT (HCC).

    Date de mise en ligne : Vendredi 01 septembre 2017
    Dong Hyun Sinn, Danbee Kang, Hye Ryoun Jang, Seonhye Gu, Soo Jin Cho, Seung Woon Paik, Seungho Ryu, Yoosoo Chang, Mariana Lazo, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
    Development of Chronic Kidney Disease in patients with Non-alcoholic Fatty Liver Disease: A Cohort Study
    The presence of non-alcoholic fatty liver disease was associated with the future decline of renal function.

    Date de mise en ligne : Vendredi 01 septembre 2017
    Meng Wang, Guannan Shen, Liangguo Xu, Xiaodong Liu, Jared M. Brown, Dechun Feng, Ruth Ann Ross, Bin Gao, Suthat Liangpunsakul, Cynthia Ju
    IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-κB activation in hepatic macrophages
    Alcoholic liver disease (ALD) is a major chronic liver disorder that can progress from mild hepatic inflammation/injury to more severe manifestations including alcoholic hepatitis, cirrhosis and hepatocellular carcinoma. (1) The severe forms of ALD result in end-stage decompensated liver disease in approximately one third of heavy drinkers. [1,2] Ample evidence supports that hepatic inflammation plays a critical role in the underlying pathogenesis of ALD. [3] Alcohol consumption increases intestinal permeability, leading to the hepatic translocation of pathogen-associated molecular pattern molecules (PAMPs).

    Date de mise en ligne : Vendredi 01 septembre 2017
    Sabine K. Urban, Marcin Krawczyk, Arnulf Willms, Hanna Sänger, Frank Lammert, Jesus M. Banales, Piotr Milkiewicz, Veronika Lukacs-Kornek, Miroslaw Kornek
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma
    We thank Ponziani et al. for highlighting our publication on large extracellular vesicles in liver tumours [1] and agree on their conclusions and final remarks. We would also like to congratulate them on their previous publication, reporting that early recurrence of hepatocellular carcinoma (HCC) after R0 resection correlates with high levels of HepPar1 positive microparticles (MPs), providing a potential biomarker for monitoring early HCC recurrence [2].

    Date de mise en ligne : Vendredi 01 septembre 2017
    Jing Wang, Yiqi Yu, Guojun Li, Chuan Shen, Zhefeng Meng, Jianming Zheng, Yanhong Jia, Shaolong Chen, Xiao Zhang, MengQi Zhu, Jiangjiang Zheng, Zhangzhang Song, Jing Wu, Lingyun Shao, Peiyu Qian, Xiaona Mao, Xuanyi Wang, Yuxian Huang, Caiyan Zhao, Jiming Zhang, Chao Qiu, Wenhong Zhang
    Relationship between serum HBV RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients
    Hepatitis B virus (HBV) infection is associated with significant morbidity and mortality. At present, 240 million people are estimated to have chronic hepatitis B (CHB) infection worldwide[1,2]. Considering this large prevalence, monitoring viral replication activity is a vital part of the clinical management of CHB infection. Thus far, serum HBV-DNA load is the only licensed laboratory indicator that directly indicates the quantity of circulating viral particles, thereby reflecting the activity of viral production in the liver[3,4].

    Date de mise en ligne : Vendredi 01 septembre 2017
    Glenda Grossi, Alessandro Loglio, Floriana Facchetti, Marta Borghi, Roberta Soffredini, Enrico Galmozzi, Giovanna Lunghi, Anuj Gaggar, Pietro Lampertico
    Tenofovir alafenamide as a Rescue Therapy in a Cirrhotic HBV Patient with a Hystory of Fanconi Syndrome and Multidrug Resistance: A Case Report
    Tenofovir disoproxil fumarate (TDF) is a recommended first-line therapy for both naïve and experienced chronic hepatitis B (CHB) patients although reduced estimated glomerular filtration rate (eGFR), hypophosphatemia, hyperphosphaturia and Fanconi syndrome have been reported in some patients. Entecavir (ETV) could be considered as a rescue therapy for TDF treated patients developing renal dysfunction, though patients with prior history of treatment with Lamivudine (LAM) can develop ETV resistance strains which can lead to potentially severe hepatitis flares.

    Date de mise en ligne : Vendredi 01 septembre 2017
    Giovanni Targher, Sven M. Francque
    A fatty liver leads to decreased kidney function?
    It is now increasingly apparent that the global health burden of non-alcoholic fatty liver disease (NAFLD) is wide reaching. NAFLD not only affects the liver, but also the risk of developing cardiovascular disease and other extra-hepatic diseases that have a considerable impact on health care resources.1–3

    Date de mise en ligne : Vendredi 01 septembre 2017
    Francesca Romana Ponziani, Igor Giarretta, Alberto Nicoletti, Ilaria Gatto, Roberto Pola, Maurizio Pompili
    Diagnostic and Prognostic Role of Circulating Microparticles in Hepatocellular Carcinoma
    Julich-Haertel and coll. have recently published an interesting study on the possibility to use certain types of circulating microparticles (MPs) as novel biomarkers of liver cancer [1].

    Date de mise en ligne : Mardi 29 aot 2017
    Vincenza Calvaruso, Antonio Craxì
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back
    EASL guidelines on treatment of HCV and HBV hepatitis focus on the management of HCV patients with HBV coinfection [1,2]. In fact interferon-free HCV therapies with DAAs, which are the current standard of care for patients with HCV infection at all stages of disease, have been related to HBV reactivation both in the setting of HBsAg positive patient and in that of HBsAg negative subiects with occult HBV infection [3]. Biological plausibility for HBV reactivation in HCV patients under DAAs relates to the fact that DAA regimens stop HCV replication and clear the virus from hepatocytes in a few weeks or even days, according also to the efficiency of the innate antiviral immune response.

    Date de mise en ligne : Lundi 28 aot 2017
    Vincent Mallet, Julie Bruneau, Julien Zuber, Cécile Alanio, Stéphanie Leclerc-Mercier, Anne-Marie Roque-Afonso, Anke R.M. Kraft, Lucile Couronné, Dominique Roulot, Heiner Wedemeyer, Matthew L. Albert, Patrick Hillon, Liliane Laroche, Stanislas Pol, Olivier Hermine
    Hepatitis E Virus-Induced Primary Cutaneous CD30(+) T cell Lymphoproliferative Disorder
    Hepatitis E virus (HEV), the causative agent of hepatitis E, is a non-enveloped RNA virus and a member of the genus Orthohepevirus within the Hepeviridae family. There are four major HEV genotypes (1, 2, 3, and 4) that can infect humans; the preferential mode is enterically via contaminated drinking water (HEV-1, HEV-2) or infected food (HEV-3, HEV-4). HEV is endemic worldwide with areas of hyperendemicity, including in high-income countries where HEV-3 is most prevalent. [1]

    Date de mise en ligne : Dimanche 27 aot 2017
    Marie Boyle, Jelena Mann
    TEMPORARY REMOVAL: Epigenetics in Chronic Liver Disease
    The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated.The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

    Date de mise en ligne : Jeudi 24 aot 2017
    Suraj A Sharma, Matthew Kowgier, Bettina E Hansen, Willem Pieter Brouwer, Raoel Maan, David Wong, Hemant Shah, Korosh Khalili, Colina Yim, E. Jenny Heathcote, Harry L.A. Janssen, Morris Sherman, Gideon M. Hirschfield, Jordan J Feld
    Toronto HCC Risk Index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis
    Ambulatory management of cirrhosis is of increasing importance with rising rates of chronic liver disease and the associated complications of end-stage cirrhosis. One such complication, hepatocellular carcinoma (HCC), is the fifth most common malignancy among men globally, and seventh most common malignancy among women, leading to more than 700,000 deaths annually[1–3]. In the US, the age-adjusted incidence of HCC rose from 1.6 to 4.5 per 100,000 people between 1975 and 2005[4]. Currently, one-year survival for HCC is still less than 50%, despite improvements in early recognition using surveillance and the availability of better therapies[4–6].

    Date de mise en ligne : Mercredi 23 aot 2017
    Sara Torrecilla, Daniela Sia, Andrew N. Harrington, Zhongyang Zhang, Laia Cabellos, Helena Cornella, Agrin Moeini, Genis Camprecios, Wei-Qiang Leow, Maria Isabel Fiel, Ke Hao, Laia Bassaganyas, Milind Mahajan, Swan N. Thung, Augusto Villanueva, Sander Florman, Myron E. Schwartz, Josep M. Llovet
    Trunk events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma
    Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the second leading cause of cancer-related mortality worldwide [1]. Unlike other neoplasms, HCC usually arises in a previously damaged organ. Liver cirrhosis caused by well-known etiologies (i.e. HBV, HCV, alcohol consumption and metabolic syndrome) is the underlying disease in more than 80% of cases [2]. The development of HCC from cirrhosis follows a multistep process with a defined sequence of lesions, starting with the generation of low-grade and high-grade dysplastic nodules (LGDNs and HGDNs) that eventually develop into early HCC and culminate into advanced malignancy [2].

    Date de mise en ligne : Mercredi 23 aot 2017
    Laura Kramer, Anne Laurain, Philippe Sultanik, Pauline Trémeaux, Jean-François Méritet, Arielle R. Rosenberg, Stanislas Pol
    “Empirical” retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen
    Since 2011 the use of oral direct-acting antivirals (DAAs) in chronic hepatitis C virus (HCV) infection has dramatically improved the rate of HCV eradication. However, 5 to 10% of patients failed a first line of DAA regimen. Because strategies of retreatment have not been extensively evaluated, available guidelines are supported by a low level of evidence [1]. We here report our results of retreatment of patients who failed a first DAA regimen in real life.

    Date de mise en ligne : Mercredi 23 aot 2017
    Patricia Garvey, Niamh Murphy, Paula Flanagan, Aline Brennan, Garry Courtney, Orla Crosbie, John Crowe, John Hegarty, John Lee, Margaret McIver, Carol McNulty, Frank Murray, Niamh Nolan, Cliona O'Farrelly, Stephen Stewart, Michele Tait, Suzanne Norris, Lelia Thornton
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s
    Acute hepatitis C virus (HCV) infection is usually asymptomatic, with between 55% and 85% of infected persons developing chronic infection [1]. The clinical complications of HCV-induced liver disease (cirrhosis, hepatocellular carcinoma (HCC) and liver-related death) take many decades to develop; cirrhosis rates of 10-20% have been reported within 20-30 years of infection, and in persons with cirrhosis there is a 1-5% annual risk of HCC [2]. A wide range of factors have been reported to influence the rate of disease progression including age, co-infections (e.g.

    Date de mise en ligne : Mardi 22 aot 2017
    Kojiro Nakamura, Min Zhang, Shoichi Kageyama, Bibo Ke, Takehiro Fujii, Rebecca A. Sosa, Elaine F. Reed, Nakul Datta, Ali Zarrinpar, Ronald W. Busuttil, Jesus A. Araujo, Jerzy W. Kupiec-Weglinski
    Macrophage heme oxygenase-1-SIRT1-p53 Axis Regulates Sterile Inflammation in Liver Ischemia-Reperfusion Injury
    Ischemia-reperfusion injury (IRI) during liver resection, procurement and transplantation, characterized by sterile inflammation and hepatocellular death, represents a risk factor predisposing to acute and chronic rejection [1]. As one of the most challenging problems in transplantation, IRI contributes to shortage of donor organs. As the initiating events that account for tissue damage are not well understood, we have assessed TLR4-driven innate immune responses in IR-stressed murine livers [2].

    Date de mise en ligne : Mardi 22 aot 2017
    Robin Padickakudy, David Pereyra, Florian Offensperger, Philipp Jonas, Lukas Oehlberger, Christian Schwarz, Stefanie Haegele, Alice Assinger, Christine Brostjan, Thomas Gruenberger, Patrick Starlinger
    Bivalent role of Intra-Platelet Serotonin in Liver Regeneration and Tumor Recurrence in Humans
    To date liver resection is known to improve outcome in patients suffering from neoplastic liver diseases[1,2]. However, postoperative liver dysfunction (LD) remains an important concern as it is associated with postoperative morbidity and mortality, and ultimately with reduced overall survival (OS). To avoid postoperative LD a sufficient liver remnant has to be preserved to allow for postoperative liver regeneration[3]. Several attempts have been made to characterize pathophysiological processes involved in human liver regeneration to identify novel therapeutic targets that might be modified to promote postoperative liver regeneration.

    Date de mise en ligne : Mardi 22 aot 2017
    Juan Manuel Pascasio, Carmen Vinaixa, María Teresa Ferrer, Jordi Colmenero, Angel Rubin, Lluis Castells, María Luisa Manzano, Sara Lorente, Milagros Testillano, Xavier Xiol, Esther Molina, Luisa González-Diéguez, Elena Otón, Sonia Pascual, Begoña Santos, José Ignacio Herrero, Magdalena Salcedo, José Luis Montero, Gloria Sánchez-Antolín, Isidoro Narváez, Flor Nogueras, Álvaro Giráldez, Martín Prieto, Xavier Forns, María-Carlota Londoño
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation
    Hepatitis C (HCV) recurrence after liver transplantation (LT) is universal in patients with detectable HCV-RNA [1]. In the interferon (IFN) era, the attempts to eradicate HCV infection before transplant were hampered by the poor efficacy of IFN-based therapies and the high number of adverse events (AEs) in patients with advanced liver disease [2–4]. The development of direct-acting antivirals (DAAs) has completely changed the scenario allowing the treatment of sicker patients, including those awaiting LT.

    Date de mise en ligne : Mardi 22 aot 2017
    Muthukumarassamy Rajakannu, Audrey Coilly, René Adam, Didier Samuel, Eric Vibert
    Prospective validation of transient elastography for staging liver fibrosis in patients undergoing hepatectomy and liver transplantation
    Letter to the Editor:

    Date de mise en ligne : Mardi 22 aot 2017
    Richard J. Thompson
    Sequencing of transporter genes in cholestasis: We are still learning
    Sequencing of DNA has never been easier. It is now perfectly possible to sequence an individual’s entire genome from a few micrograms of DNA, obtained from peripheral blood or elsewhere. The cost of sequencing has also fallen dramatically. Now the biggest hurdle is in making sense of the data. Variations in DNA sequence contribute to a large part of the phenotypic differences between individuals. However most of the variation occurs in non-coding DNA; the overwhelming majority of which we cannot yet interpret.

    Date de mise en ligne : Mardi 22 aot 2017
    Derek Y. Chiang, Augusto Villanueva
    Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?
    Liver cancer incidence and mortality continue to increase.1 Hepatocellular carcinoma (HCC) is the most frequent form of liver cancer and it ranks second to last in terms of known druggable mutations.2 Thus, the need for new therapeutic approaches to treat HCC cannot be overemphasized. Recently, The Cancer Genome Atlas (TCGA) consortium released the somatic mutations and DNA copy number alterations analysis of a cohort of 363 HCC patients.3 In a subset of samples (n=196), the authors also integrated data from mRNA/miRNA expression, DNA methylation and protein expression.

    Date de mise en ligne : Mardi 22 aot 2017
    Didier Samuel, Alberto Sanchez-Fueyo
    Immunotherapy in liver transplantation
    Immunosuppressive regimens that contain calcineurin inhibitors effectively target recipient T cells, successfully prevent acute cellular rejection, and remain the mainstay immunosuppressant following liver transplantation. However, these regimens have many off target effects and are associated with significant toxicity. mTOR inhibitors provide some advantages over calcineurin inhibitors (e.g. anticancer properties, reduced nephrotoxicity), but have many other side effects, and are mainly used to reduce the overall calcineurin inhibitor exposure.

    Date de mise en ligne : Jeudi 17 aot 2017
    Sonja Gordic, Idoia Corcuera-Solano, Ashley Stueck, Cecilia Besa, Pamela Argiriadi, Preethi Guniganti, Michael King, Shingo Kihira, James Babb, Swan Thung, Bachir Taouli
    Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology
    Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and is the third most common cause of cancer-related mortality1 with a rising incidence in the United States.2 Radical treatment options such as liver transplantation and surgical resection are available only in a small number of HCC cases. Liver transplantation is usually performed in patients with cirrhosis and HCC within the Milan criteria.3 The limited availability of donor organs prolongs the waiting time and thus increases the chance of dropout because of tumor progression.

    Date de mise en ligne : Mercredi 16 aot 2017
    Salvatore Petta, Giulio Marchesini
    Corrigendum to “Coffee and tea breaks for liver health” [J Hepatol 67 (2017) 221–223]
    It has come to our attention that the authors name of the original article “Coffee and Herbal Tea Consumption is associated with lower Liver Stiffness in the General Population: The Rotterdam Study” in which this editorial refers to was misspelt in the Editorial. The correct spelling of the author is Alferink. We apologise for this error and the inconvenience caused.

    Date de mise en ligne : Vendredi 11 aot 2017
    Sandra Rebouissou, Jessica Zucman-Rossi, Richard Moreau, Zhixin Qiu, Lijian Hui
    Note of caution: Contaminations of hepatocellular cell lines
    Cell lines derived from human primary liver tumours are very important tools for developing pre-clinical models and performing functional validation on specific genes, proteins and pathways. More than one hundred cell lines derived from hepatocellular carcinoma (HCC) have been listed in the Cellosaurus database (Release: Version 22 May 2017; http://web.expasy.org/cellosaurus/). Overall, the number of available cell lines is limited by the efficiency of cell growth in vitro after tumour dissociation.

    Date de mise en ligne : Jeudi 10 aot 2017
    Teh-Ia Huo, Chia-Yang Hsu, Po-Hong Liu
    Performance status in patients with HCC: New kid on the block
    We read with interest the paper “The treatment of intermediate stage tumour beyond TACE: from surgery to systemic therapy” by Prof. Galle published in the Journal of Hepatology.1 This comprehensive review discloses the dilemma of current treatment strategy for patients with intermediate stage, or Barcelona Clinic Liver Cancer (BCLC) stage B, hepatocellular carcinoma (HCC). In addition to transarterial chemoembolization (TACE), as suggested in the BCLC scheme, various therapeutic options and their combinations have been proposed for intermediate stage HCC in real world practice.

    Date de mise en ligne : Jeudi 10 aot 2017
    Marcus-Alexander Wörns, Peter Robert Galle
    Reply to: “Performance status in patients with HCC: New kid on the block”
    We would like to thank Huo et al. for their correspondence (Performance status in patients with HCC: New kid on the block) on our recent review (The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy1).

    Date de mise en ligne : Jeudi 10 aot 2017
    Dalila Mele, Stefania Mantovani, Barbara Oliviero, Giulia Grossi, Andrea Lombardi, Mario U. Mondelli, Stefania Varchetta
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells
    Several lines of evidence indicate that natural killer (NK) cells play key roles in immune surveillance against tumors and pathogens and as regulators of adaptive immunity [1].

    Date de mise en ligne : Jeudi 10 aot 2017
    Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Ulf Hammar, Per Stål, Rolf Hultcrantz, Stergios Kechagias
    Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD
    Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide,1–3 affecting up to 25% of the global population.4

    Date de mise en ligne : Jeudi 10 aot 2017
    Maria Francesca Donato, Federica Invernizzi, Giorgio Rossi, Massimo Iavarone
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence
    Yang et al. recently reported on an increased risk of recurrence of hepatocellular carcinoma (HCC) in a small group of liver graft recipients, who received interferon-free, direct antiviral agents (DAA) for hepatitis C, while they were listed in two transplantation centers in the United States (US).1 Eighteen candidates listed for HCC liver transplant (LT) received DAA, while 63 did not; HCC recurred post-transplant in 11 recipients (13.6%) and was more frequently observed in DAA-treated recipients than untreated patients (27.8% vs.

    Date de mise en ligne : Mercredi 09 aot 2017
    Ju Dong Yang, Michael D. Leise
    Reply to: “Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence”
    We read the letter from Donato et al. regarding our recent publication.1 In their research letter, the authors investigated the impact of pre-liver transplant (LT) direct acting anti-viral (DAA) treatment with sofosbuvir containing regimens on post-LT cancer recurrence in 35 patients with hepatitis C virus (HCV) associated hepatocellular carcinoma (HCC). The only real control group in this study included 10 patients with HCC who did not receive DAA treatment. In contrast to the results reported in our previous study, post-LT recurrence of HCC was only seen in 8.5% of patients after a median follow-up of 20months, which was similar to the 10% recurrence rates seen in the non-DAA treatment group.

    Date de mise en ligne : Mercredi 09 aot 2017
    Reem Waziry, Behzad Hajarizadeh, Jason Grebely, Janaki Amin, Matthew Law, Mark Danta, Jacob George, Gregory J. Dore
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
    Primary liver cancer is the fifth most common cancer in men, and the ninth in women.1 The alarmingly poor prognosis enhances the burden of primary liver cancer; the third leading cause of cancer mortality in 2013.2 In high-income countries, an increasing proportion of the most common type of primary liver cancer, hepatocellular carcinoma (HCC), is attributed to hepatitis C virus (HCV) infection.3,4 Opportunities to increase the uptake of direct-acting antiviral (DAA) therapy are among the most promising strategies for reducing the future burden of HCC.

    Date de mise en ligne : Mercredi 09 aot 2017
    Avik Majumdar, Michael Bailey, William M. Kemp, Rinaldo Bellomo, Stuart K. Roberts, David Pilcher
    Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015
    Patients with liver cirrhosis admitted to intensive care units (ICUs) have historically been regarded as having a universally poor prognosis, with hospital mortality rates up to 89% in early studies. [1,2] However, hospital mortality for this group appears to have improved over the past decade, varying from 35% to 47% in referral centres. [3–6] Higher mortality has been described in cirrhotic patient subgroups, such as those with sepsis or requiring mechanical ventilation. [7,8] Annually, approximately 26,000 patients with cirrhosis require ICU support in the United States at a cost of $3 billion.

    Date de mise en ligne : Mercredi 09 aot 2017
    Tom H. Karlsen, Trine Folseraas, Douglas Thorburn, Mette Vesterhus
    Primary sclerosing cholangitis – a comprehensive review
    Primary sclerosing cholangitis (PSC) is a rare disorder characterized by multi-focal bile duct strictures and progressive liver disease. Inflammatory bowel disease (IBD) is usually present and there is a high risk of cholangiocarcinoma and colorectal cancer. With no effective medical therapy, most patients ultimately require liver transplantation, after which disease recurrence may occur. With limited therapeutic options and lack of proven surveillance strategies, patients experience significant unmet needs.

    Date de mise en ligne : Lundi 07 aot 2017
    Sebastian Mueller, Johannes Mueller
    Reply to: “Is room temperature susceptometry really an accurate method to assess hepatocellular iron?”
    We acknowledge the letter from Dr. Paisant et al. and thank them for their comments in response to our paper “Sensitive and noninvasive assessment of hepatocellular iron using a novel room temperature susceptometer”.1 However, we do not accept the idea of being more cautious with the interpretation. We not only performed a prospective study on a large and heterogeneous cohort that was carefully characterized for fibrosis stage and steatosis using transient elastography (TE) and controlled attenuation parameter (CAP), it also included a wide array of in vitro experiments.

    Date de mise en ligne : Samedi 05 aot 2017
    Ana da Silva Filipe, Vattipally Sreenu, Joseph Hughes, Elihu Aranday-Cortes, William L. Irving, Graham R. Foster, Kosh Agarwal, William Rosenberg, Douglas Macdonald, Paul Richardson, Mark A. Aldersley, Martin Wiselka, Andrew Ustianowski, John McLauchlan, Emma C. Thomson
    Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries
    We read with interest “NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome” by Zeuzem et al. in the Journal of Hepatology, which indicated lower sustained virologic response (SVR) rates for Gt1a and Gt1b strains carrying multiple resistance-associated substitutions (RASs) in NS5A.1 Their study is very comprehensive but, as the authors note, it is largely restricted to hepatitis C virus (HCV) subtypes Gt1a and Gt1b, and does not represent subtypes from large geographical regions, including Africa.

    Date de mise en ligne : Samedi 05 aot 2017
    Ulrich Thalheimer, Valerio Giannelli, Claire Francoz, Sergio Maimone
    Non selective beta blockers in cirrhosis
    We read with great interest the article by Drs Reiberger and Mandorfer about the use of non selective beta blockers (NSBBs) in decompensated cirrhosis.1 We would like to commend them for this well researched and surprisingly balanced review of a topic known to have caused controversy in the scientific community.2,3 Indeed, we hope that this review will succeed in allaying some of the fears which may have been raised about the use of NSBBs, a class of drugs we believe to be beneficial in patients with cirrhosis, beyond their effectiveness in reducing portal hypertension,4 to a point where propranolol has been termed “the hepatologist’s aspirin”.

    Date de mise en ligne : Samedi 05 aot 2017
    Anita Paisant, Fabrice Lainé, Yves Gandon, Edouard Bardou-Jacquet
    Is room temperature susceptometer really an accurate method to assess hepatocellular iron?
    We read with interest the study by Mueller et al. describing the use of room temperature susceptometer (RTS) to assess hepatic iron content (HIC).1 This is an interesting clinical application of the methods described by Avrin et al.2,3 This topic is relevant as there is still a need for a cost-effective and efficient iron quantification method in liver disease.

    Date de mise en ligne : Samedi 05 aot 2017
    Stefan Zeuzem, Hadas Dvory-Sobol, Diana M. Brainard
    Reply to: “Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries”
    We thank da Silva Filipe et al. for their interest in our study, and for sharing their virologic analysis of genotype (GT)1l (n=3) and GT4r (n=2) patients infected with hepatitis C virus (HCV) who failed to achieve sustained virologic response (SVR) following direct-acting antiviral (DAA) treatment through the NHS England Early Access Program, which enrolled patients with decompensated cirrhosis, a factor relevant in interpreting treatment outcome to DAA therapies. Their data highlight the importance of reporting outcomes among patients with less common genotype subtypes.

    Date de mise en ligne : Samedi 05 aot 2017
    Mattias Mandorfer, Thomas Reiberger
    Reply to: “Non selective beta blockers in cirrhosis”
    We would like to thank Dr. Thalheimer et al. for their interest in our Grand Rounds article1 and for sharing their valuable thoughts on the use of non selective β blockers (NSBB) in patients with cirrhosis.2

    Date de mise en ligne : Mardi 01 aot 2017
    Anna S. Lok, Fabien Zoulim, Geoffrey Dusheiko, Marc G. Ghany
    Hepatitis B cure: From discovery to regulatory approval
    The majority of persons currently treated for chronic hepatitis B require long-term or lifelong therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and immune modulatory therapies are in development. The introduction of these novel compounds for chronic hepatitis B necessitates a standardised appraisal of the efficacy and safety of these treatments and definitions of new or additional endpoints to inform clinical trials. To move the field forward and to expedite the pathway from discovery to regulatory approval, a workshop with key stakeholders was held in September 2016 to develop a consensus on treatment endpoints to guide the design of clinical trials aimed at hepatitis B cure.

    Date de mise en ligne : Vendredi 28 juillet 2017
    Jeffrey V. Lazarus, Stefan Wiktor, Massimo Colombo, Mark Thursz, EASL International Liver Foundation
    Micro-elimination – A path to global elimination of hepatitis C
    In May 2016, the World Health Organization (WHO) released its first global strategy on viral hepatitis.1 It takes the Sustainable Development Goal of simply “combatting” hepatitis and makes it more concrete and ambitious – most notably by calling for the elimination of the hepatitis C virus (HCV) and hepatitis B virus as public health threats by 2030. The strategy defines elimination as an 80% reduction in new HCV infections and a 65% reduction in HCV mortality.

    Date de mise en ligne : Vendredi 21 juillet 2017
    Tsuyoshi Suda, Tetsuro Shimakami, Takayoshi Shirasaki, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
    Reactivation of hepatitis B virus from an isolated anti-HBc positive patient after eradication of hepatitis C virus with direct-acting antiviral agents
    Direct-acting antiviral agents (DAAs), called “interferon-free treatment”, for hepatitis C virus (HCV) have greatly improved our ability to eradicate HCV from infected livers.

    Date de mise en ligne : Vendredi 21 juillet 2017
    Sunyoung Lee, Seong Hyun Kim
    Reply to: “How to better predict microvascular invasion and recurrence of hepatocellular carcinoma”
    We thank Xu et al. for their interest in our recent study about preoperative gadoxetic acid–enhanced magnetic resonance imaging for predicting microvascular invasion in patients with single hepatocellular carcinoma,1 and we appreciate their comments.

    Date de mise en ligne : Jeudi 20 juillet 2017
    Xin-Fei Xu, Jiong-Jie Yu, Hao Xing, Feng Shen, Tian Yang
    How to better predict microvascular invasion and recurrence of hepatocellular carcinoma
    We read with great interest the article by Dr. Lee et al.1 This retrospective study showed that three characteristic features of Magnetic Resonance Imaging (MRI) were independent predictors of microvascular invasion (MVI) in single hepatocellular carcinoma (HCC): arterial peritumoral enhancement, non-smooth tumor margin, and peritumoral hypointensity on hepatobiliary phase, which can be used as a biomarker for predicting MVI. In addition, this study also revealed that a combination of any two of these imaging features was associated with early postoperative recurrence of HCC.

    Date de mise en ligne : Jeudi 20 juillet 2017
    Thomas Berg, Karl-Georg Simon, Stefan Mauss, Eckart Schott, Renate Heyne, Dietmar M. Klass, Christoph Eisenbach, Tania Mara Welzel, Reinhart Zachoval, Gisela Felten, Julian Schulze-zur-Wiesch, Markus Cornberg, Marjoleine L. Op den Brouw, Belinda Jump, Hans Reiser, Lothar Gallo, Tobias Warger, Jörg Petersen, FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study
    Although there is currently no cure for chronic hepatitis B virus (HBV) infection, the virus can be effectively controlled with current antiviral treatment strategies using either interferon (IFN) or nucleos(t)ide analogues (NA). Treatment for chronic HBV therefore aims to provide sustained suppression of viral replication, thus lessening the risk of fibrosis progression and decreasing the risk of hepatocellular carcinoma (HCC).1 The ideal endpoint of treatment for hepatitis B ‘e’ antigen (HBeAg)-positive patients is HBeAg seroconversion; this is sometimes followed by hepatitis B surface antigen (HBsAg) loss, which is considered to be the closest to clinical cure of chronic HBV infection.

    Date de mise en ligne : Jeudi 20 juillet 2017
    Neil Rajoriya, Christophe Combet, Fabien Zoulim, Harry L.A. Janssen
    How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?
    Chronic hepatitis B virus (HBV) infection remains a global problem. Several HBV (sub)genotypes exist with different biology and geographical preponderances. While the future aim of HBV treatment remains virus eradication, current strategies of treatment aim to suppress the virus and prevent the progression of liver disease. Current strategies also involve identification of patients for treatment – those at risk of progressive liver disease. Identification of HBV genotype, HBV mutants and other predictive factors allow for tailored treatments, and also risk-surveillance pathways such as for hepatocellular cancer screening.

    Date de mise en ligne : Mercredi 19 juillet 2017
    Harry R. Dalton, Jeroen J.J. van Eijk, Pascal Cintas, Richie G. Madden, Catherine Jones, Glynn W. Webb, Benjamin Norton, Julie Pique, Suzanne Lutgens, Nikki Devooght-Johnson, Kathy Woolson, John Baker, Maria Saunders, Liz Househam, James Griffiths, Florence Abravanel, Jacques Izopet, Nassim Kamar, Nens van Alfen, Baziel G.M. van Engelen, Jeremy G. Hunter, Annemiek A. van der Eijk, Richard P. Bendall, Brendan N. Mclean, Bart C. Jacobs
    Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study
    Hepatitis E virus (HEV) is endemic in many developed countries. In such settings, infection is mostly caused by HEV genotypes 3 and 4 (gt3 and 4) and is considered to be largely zoonotic with pigs as the usual source. Locally-acquired HEV infection is mostly (∼95%) asymptomatic but may result in clinically evident hepatitis that mainly affects older males.1,2 Chronic infection has also been documented in immunosuppressed patients including transplant recipients, those undergoing chemotherapy for haematological malignancy, and people living with HIV.

    Date de mise en ligne : Mercredi 19 juillet 2017
    William M. Lee
    Acetaminophen (APAP) hepatotoxicity—Isn’t it time for APAP to go away?
    Acetaminophen (APAP) is the most commonly used drug for the treatment of pain and fever around the world. At the same time, APAP can cause dose-related hepatocellular necrosis, responsible for nearly 500 deaths annually in the United States (US) alone, as well as 100,000 calls to US Poison Control Centers, 50,000 emergency room visits and 10,000 hospitalisations per year. As an over-the-counter and prescription product (with opioids), APAP toxicity dwarfs all other prescription drugs as a cause of acute liver failure in the US and Europe, but it is not regulated in any significant way.

    Date de mise en ligne : Mardi 18 juillet 2017
    Jean-Charles Nault, Valérie Paradis, Daniel Cherqui, Valérie Vilgrain, Jessica Zucman-Rossi
    Molecular classification of hepatocellular adenoma in clinical practice
    Hepatocellular adenomas (HCA) are rare benign liver tumors occurring in young women taking contraception. They are associated with rare complications such as bleeding or malignant transformation into hepatocellular carcinoma. A molecular classification has divided HCA in several subgroups linked with risk factors, clinical behaviour, histological features and imaging: HNF1A inactivated HCA, Inflammatory HCA, CTNNB1 mutated HCA in exon 3, CTNNB1 mutated in exon 7 and 8 HCA, sonic hedgehog HCA and unclassified HCA.

    Date de mise en ligne : Mardi 18 juillet 2017
    Salvatore Piano, Marta Tonon, Elia Vettore, Marialuisa Stanco, Chiara Pilutti, Antonietta Romano, Sara Mareso, Carmine Gambino, Alessandra Brocca, Antonietta Sticca, Silvano Fasolato, Paolo Angeli
    Incidence, predictors and outcomes of acute-on-chronic liver failure in outpatients with cirrhosis
    Liver cirrhosis is the most advanced stage of chronic liver disease and represents a leading cause of mortality in adults, resulting in 1.03million deaths per year worldwide.1 For several years, cirrhosis has been considered a progressive disease characterized by a compensated phase followed by a decompensated phase and resulting invariably in death. In the last 20years, with the development of effective etiological treatments this concept has been overcome and cirrhosis has been considered a dynamic disease across compensated and decompensated stages.

    Date de mise en ligne : Mardi 18 juillet 2017
    Philippe Kolly, Oliver Waidmann, Johannes Vermehren, Christophe Moreno, Isabelle Vögeli, Thomas Berg, David Semela, Stefan Zeuzem, Jean-François Dufour
    Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study
    The introduction of direct antiviral drugs (DAAs) has revolutionized the treatment of hepatitis C virus (HCV), with sustained virologic response rates of more than 90% in most patient populations.1 However, it has been suggested that interferon-free HCV eradication may be more harmful than beneficial in a subgroup of patients. In patients with prior curative hepatocellular carcinoma (HCC) therapy, an increased tumour recurrence rate following DAA-based HCV therapy has been reported.2,3

    Date de mise en ligne : Mardi 18 juillet 2017
    Shanshan Zhang, Xinhua Song, Dan Cao, Zhong Xu, Biao Fan, Li Che, Junjie Hu, Bin Chen, Mingjie Dong, Maria G. Pilo, Antonio Cigliano, Katja Evert, Silvia Ribback, Frank Dombrowski, Rosa M. Pascale, Antonio Cossu, Gianpaolo Vidili, Alberto Porcu, Maria M. Simile, Giovanni M. Pes, Gianluigi Giannelli, John Gordan, Lixin Wei, Matthias Evert, Wenming Cong, Diego F. Calvisi, Xin Chen
    Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice
    Intrahepatic cholangiocarcinoma (ICC) is the second most common liver tumor, whose incidence is rapidly rising in Western countries.1 Patients with ICC are commonly diagnosed at advanced stages. This excludes them from surgical resection, the only possible curative treatment.2 A gemcitabine/oxaliplatin-based regimen is used as a standard chemotherapy for advanced ICC, but its efficacy is rather limited.3 Therefore, there is an urgent need to develop novel therapeutic strategies for the treatment of this lethal malignancy.

    Date de mise en ligne : Mardi 18 juillet 2017
    Carola Dröge, Michele Bonus, Ulrich Baumann, Caroline Klindt, Elke Lainka, Simone Kathemann, Florian Brinkert, Enke Grabhorn, Eva-Doreen Pfister, Daniel Wenning, Alexander Fichtner, Daniel N. Gotthardt, Karl Heinz Weiss, Patrick McKiernan, Ratna Dua Puri, IC Verma, Stefanie Kluge, Holger Gohlke, Lutz Schmitt, Ralf Kubitz, Dieter Häussinger, Verena Keitel
    Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants
    The three transport proteins familial intrahepatic cholestasis 1 (FIC1, gene symbol: ATP8B1), bile salt export pump (BSEP, ABCB11) and multidrug resistance p-glycoprotein 3 (MDR3, ABCB4) are located in the canalicular membrane of hepatocytes and mediate bile formation. The FIC1 protein is encoded by the ATP8B1 gene on chromosome 18q21 and represents a P-type ATPase, flipping aminophospholipids from the outer to the inner membrane leaflet thereby maintaining membrane asymmetry, which is essential for the function of other canalicular transport proteins [1–4].

    Date de mise en ligne : Vendredi 14 juillet 2017
    Maria Kulecka, Aldona Wierzbicka, Agnieszka Paziewska, Michal Mikula, Andrzej Habior, Wojciech Janczyk, Michalina Dabrowska, Jakub Karczmarski, Michal Lazniewski, Krzysztof Ginalski, Anna Czlonkowska, Piotr Socha, Jerzy Ostrowski
    A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase
    Macroenzymes, serum high-molecular-weight compounds that are formed by polymerization or association with other serum constituents (primarily immunoglobulins1), are rare in the general healthy population.2 There is evidence that they may be associated with hepatitis C;3 autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, ulcerative colitis, and celiac disease;4–8 and neoplastic disorders.1,9 A typical macroenzyme is the macroenzyme form of aspartate aminotransferase (macro-AST), the presence of which is generally characterized by increased serum AST activity.

    Date de mise en ligne : Vendredi 14 juillet 2017
    Roberto Carnevale, Valeria Raparelli, Cristina Nocella, Simona Bartimoccia, Marta Novo, Anna Severino, Elena De Falco, Vittoria Cammisotto, Chiara Pasquale, Clara Crescioli, Antonio Sili Scavalli, Oliviero Riggio, Stefania Basili, Francesco Violi
    Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis
    Coagulopathy is a term coined to define a close relationship between cirrhosis and clotting changes such as prolongation of prothrombin time (PT) and activated partial thromboplastin time (aPTT), which would predispose to bleeding.1 In the recent two decades, however, the concept of a relationship between clotting changes and bleeding has been challenged for several reasons: 1) a relationship between clotting changes and bleeding has never been firmly demonstrated; and 2) apart from gastrointestinal bleeding, which is dependent on hemodynamic changes in portal circulation, spontaneous and provoked bleedings are relatively rare.

    Date de mise en ligne : Jeudi 06 juillet 2017
    V. Nobili, A. Mosca, E. Scorletti, C.D. Byrne
    Reply to: “Fructose, uric acid and zonal differences in NASH”
    We read with interest the letter by Mann & Armstrong, referring to our article entitled “Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents”.1,2 The liver has a unique dual blood supply, receiving both arterial blood and blood from the portal vein. This phenomenon and the liver cellular architecture results in hepatocytes being exposed to differential oxygen tensions and varying concentrations of dietary nutrients, according to their position across the liver lobule.

    Date de mise en ligne : Jeudi 06 juillet 2017
    Sven Stengel, Andreas Stallmach, Klaus Richter, Andreas Landrock, Jochen Hampe, Tony Bruns
    Serum metabolic signatures in patients with overt hepatic encephalopathy
    We read with great interest the study by Weiss et al.1 using liquid chromatography coupled to high-resolution mass spectrometry in order to characterize the cerebrospinal fluid (CSF) metabolome in patients with overt hepatic encephalopathy (OHE). By comparing the metabolic fingerprints in CSF from patients with OHE to neurologically healthy individuals, their data suggest a critical role of brain energy metabolism in the pathogenesis of this syndrome. Most of the identified CSF metabolites were also regulated in plasma samples from cirrhotic patients with OHE, when compared to healthy controls.

    Date de mise en ligne : Jeudi 06 juillet 2017
    J.P. Mann, M.J. Armstrong
    Fructose, uric acid, and zonal differences in NASH
    We read with interest the article by Mosca et al. on the association between fructose consumption, uric acid concentration, and paediatric non-alcoholic steatohepatitis (NASH).1 The authors used a well characterised cohort of patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD), in whom they measured serum uric acid concentrations and estimated fructose intake using a dietary questionnaire. Fructose intake and uric acid concentrations were higher in patients with definite NASH, which was defined as a NAFLD Activity Score (NAS) of ⩾5 and was confirmed using the FLIP algorithm.

    Date de mise en ligne : Jeudi 06 juillet 2017
    Pascal Gavriilidis, Keith J. Roberts, Alan Askari, Robert P. Sutcliffe, Teh-la Huo, Po-Hong Liu, Ernest Hidalgo, Philippe Compagnon, Chetana Lim, Daniel Azoulay
    Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument
    In 2011, the Institute of Medicine (USA) revised the 21-year-old definition of clinical practice guidelines as follows, “clinical practice guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of the evidence and an assessment of the benefits and harms of alternative care options”.1

    Date de mise en ligne : Jeudi 06 juillet 2017
    Palak J. Trivedi, Irene Scalera, Emma Slaney, Richard W. Laing, Bridget Gunson, Gideon M. Hirschfield, Andrea Schlegel, James Ferguson, Paolo Muiesan
    Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis
    Primary sclerosing cholangitis (PSC) is a progressive fibro-inflammatory cholangiopathy stigmatised by a disproportionate impact on young patients.1,2 Currently, liver transplantation is the only proven life-extending intervention, and PSC now accounts for 10–15% of all liver transplant activities within Europe.3–5 In parallel, the overall number of patients with chronic liver disease on an active liver transplant register is increasing globally,4–6 without an appropriate rise in the donor pool.

    Date de mise en ligne : Mercredi 05 juillet 2017
    Nicolas Weiss, Benoit Colsch, François Fenaille, Christophe Junot, Dominique Thabut
    Metabolic signature for severe cirrhosis with inflammation or hepatic encephalopathy: Do we really face two different entities?
    We thank Dr Stengel et al. for their positive comments about our article. Even if some improvements have been made in the understanding of the pathophysiology of hepatic encephalopathy (HE) in the last decades, several issues are still not addressed (see1 for short review). Thus, aside from the main role of hyperammonemia, the role of systemic inflammation and energy brain failure was recently pointed out.2–4 The latest guidelines emphasized the need to seek a differential diagnosis when the diagnosis of HE is suspected.

    Date de mise en ligne : Mardi 04 juillet 2017
    Jordi Bruix, Ann-Lii Cheng, Gerold Meinhardt, Keiko Nakajima, Yoriko De Sanctis, Josep Llovet
    Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
    The incidence of hepatocellular carcinoma (HCC) has been steadily rising and is currently the third leading cause of cancer-related deaths, with approximately 750,000 deaths reported in 2012.1 Overall, the 5-year survival rate for patients with HCC is less than 20%.2 For patients with early-stage HCC, curative treatments, such as surgical resection and radiofrequency ablation are recommended.3–7 However, most patients with HCC present at intermediate and advanced stages when these therapies are no longer effective.

    Date de mise en ligne : Lundi 03 juillet 2017
    Hasina Samji, Amanda Yu, Margot Kuo, Maryam Alavi, Ryan Woods, Maria Alvarez, Gregory J. Dore, Mark Tyndall, Mel Krajden, Naveed Z. Janjua, BC Hepatitis Testers Cohort Team
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development
    An estimated 230,000–450,000 (0.66%–1.3%) Canadians are infected with hepatitis C virus (HCV) and 43,000–181,000 (0.2%–0.8%) with hepatitis B virus (HBV).1 Effective HBV therapy and the advent of highly effective and well-tolerated direct-acting antiviral agents (DAAs) for the treatment of HCV infections2,3 have created an unprecedented opportunity to treat and/or cure HBV and HCV. However, many of those with HBV and a large proportion of individuals with HCV remain undiagnosed and are therefore unable to benefit from these clinical advances.

    Date de mise en ligne : Lundi 03 juillet 2017
    Bernhard Scheiner, Gregor Lindner, Thomas Reiberger, Bruno Schneeweiss, Michael Trauner, Christian Zauner, Georg-Christian Funk
    Acid-base disorders in liver disease
    Alongside the kidneys and lungs, the liver has been recognised as an important regulator of acid-base homeostasis. While respiratory alkalosis is the most common acid-base disorder in chronic liver disease, various complex metabolic acid-base disorders may occur with liver dysfunction. While the standard variables of acid-base equilibrium, such as pH and overall base excess, often fail to unmask the underlying cause of acid-base disorders, the physical–chemical acid-base model provides a more in-depth pathophysiological assessment for clinical judgement of acid-base disorders, in patients with liver diseases.

    Date de mise en ligne : Vendredi 30 juin 2017
    Martin Beck, Peter Schirmacher, Stephan Singer
    Alterations of the nuclear transport system in hepatocellular carcinoma – New basis for therapeutic strategies
    Hepatocellular carcinoma (HCC) is among the most prevalent human malignancies worldwide with rising incidence in industrialised countries, few therapeutic options and poor prognosis. To expand and improve therapeutic strategies, identification of drug targets involved in several liver cancer-related pathways is crucial. Virtually all signal transduction cascades cross the nuclear envelope and therefore require components of the nuclear transport system (NTS), including nuclear transport receptors (e.g.

    Date de mise en ligne : Jeudi 29 juin 2017
    European Association for the Study of the Liver
    Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C
    EASL, the European Association for the Study of the Liver, one of the world leading associations of liver specialists, feels compelled to express its serious concerns after the recent publication of a Cochrane Group systematic review entitled “Direct acting antivirals for chronic hepatitis C” by Jakobsen et al. After reviewing 138 clinical trials, including 25,232 participants, the authors conclude that: “Overall, direct acting antivirals (DAAs) on the market or under development do not seem to have any effects on risk of serious adverse events.

    Date de mise en ligne : Mercredi 28 juin 2017
    Sven H. Loosen, Christoph Roderburg, Katja L. Kauertz, Inês Pombeiro, Catherine Leyh, Fabian Benz, Mihael Vucur, Thomas Longerich, Alexander Koch, Till Braunschweig, Tom F. Ulmer, Christoph Heidenhain, Frank Tacke, Marcel Binnebösel, Maximilian Schmeding, Christian Trautwein, Ulf P. Neumann, Tom Luedde
    Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma
    Cholangiocarcinoma (CCA) represents the most common biliary tract malignancy and the second most common primary tumour of the liver, accounting for 10–20% of all primary liver cancers.1,2 Classified into three subgroups according to the anatomical location (intrahepatic, perihiliar and distal), all types of CCA share a dismal prognosis with a 5-year survival rate below 5% for advanced tumour stages.3,4 The overall global incidence of CCA shows large geographical variations between 0.5 and 85 cases per 100,000 population and has steadily increased over the last decades.

    Date de mise en ligne : Lundi 26 juin 2017
    Johanne Poisson, Fanny Turon, Christophe Marzac, Dominique-Charles Valla, Juan-Carlos Garcia-Pagan, Pierre-Emmanuel Rautou
    Reply to: “Calreticulin mutations and their importance in Budd-Chiari syndrome”
    We thank Jain Abhinav et al.1 for their letter “Calreticulin mutations and their importance in Budd-Chiari syndrome”, raising the hypothesis that the type of CALR mutation may influence the haematological phenotype in patients with splanchnic vein thrombosis.

    Date de mise en ligne : Lundi 26 juin 2017
    Abhinav Jain, Pratik Tibdewal, Akash Shukla
    Calreticulin mutations and their importance in Budd-Chiari syndrome
    We have read your recent publications on Calreticulin (CALR) gene mutations in splanchnic vein thrombosis with great interest. Poisson et al.1 reported prevalence of myeloproliferative neoplasms in a cohort of 99 patients with Budd-Chiari syndrome (BCS), out of which 28 had JAK2V617F gene mutations and one had a CALR gene mutation. The authors suggested that a combination of spleen height ≥16cm and platelet count >200×109/L be tested for CALR mutation, in the absence of JAK2 gene mutations. Turon et al.

    Date de mise en ligne : Samedi 24 juin 2017
    Terry Cheuk-Fung Yip, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Yee-Kit Tse, Kelvin Long-Yan Lam, Grace Lai-Hung Wong
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
    Chronic hepatitis B (CHB) is the leading cause of hepatocellular carcinoma (HCC) worldwide.1 Hepatitis B surface antigen (HBsAg) seroclearance is a surrogate of ultimate immune control of hepatitis B virus (HBV). The annual incidence of spontaneous HBsAg seroclearance varies from 0.12% to 2.38% in Asian cohorts and from 0.54% to 1.98% in Western cohorts.2 The rate and durability of HBsAg seroclearance induced by nucleos(t)ide analogues (NA) were recently found to be similar to those developed spontaneously.

    Date de mise en ligne : Mercredi 21 juin 2017
    Mark Kin Fai Ma, Eunice Yuen Ting Lau, Doris Hoi Wing Leung, Jessica Lo, Nicole Pui Yu Ho, Lily Kwan Wai Cheng, Stephanie Ma, Chi Ho Lin, John A. Copland, Jin Ding, Regina Cheuk Lam Lo, Irene Oi Lin Ng, Terence Kin Wah Lee
    Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation
    Liver cancer (hepatocellular carcinoma, HCC) is one of the deadliest diseases, being the fifth most commonly diagnosed cancer and second leading cause of cancer mortality in the world.1 The frontline treatment for this disease is liver transplantation and surgical resection. Despite intensive research into better therapeutic options, the only success so far is with the use of multi-kinase inhibitor sorafenib. It is the only drug currently approved by the FDA and serves as the standard treatment for HCC patients in advanced stages.

    Date de mise en ligne : Mercredi 21 juin 2017
    Veronica Marin, Kyle Poulsen, Gemma Odena, Megan R. McMullen, Jose Altamirano, Pau Sancho-Bru, Claudio Tiribelli, Juan Caballeria, Natalia Rosso, Ramon Bataller, Laura E. Nagy
    Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients
    Excessive alcohol consumption is the primary cause of liver-related mortality in Western countries.1 Alcoholic hepatitis (AH) is the most severe form of alcoholic liver disease (ALD) and there is an urgent need to develop novel targeted therapies for severe AH.2 Multiple molecular and cellular mechanisms contribute to the development of ALD. Prolonged alcohol abuse leads to an imbalance between intracellular antioxidant defense systems and the production of free radical species, promoting lipid peroxidation.

    Date de mise en ligne : Mercredi 21 juin 2017
    Thierry Gustot, Javier Fernandez, Gyongyi Szabo, Agustin Albillos, Alexandre Louvet, Rajiv Jalan, Richard Moreau, Christophe Moreno
    Sepsis in alcohol-related liver disease
    Alcohol-related liver disease (ALD) remains the most important cause of death due to alcohol. Infections, particularly bacterial infections, are one of the most frequent and severe complications of advanced ALDs, such as alcoholic cirrhosis and severe alcoholic hepatitis (sAH). The specific mechanisms responsible for this altered host defence are yet to be deciphered. The aim of the present study is to review the current knowledge of infectious complications in ALD and its pathophysiological mechanisms, distinguishing the role of alcohol consumption and the contribution of different forms of ALD.

    Date de mise en ligne : Mercredi 21 juin 2017
    Xiao Xiang, Xue-Mei You, Jian-Hong Zhong, Le-Qun Li
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection
    We were excited to read the impressive article just published in Journal of Hepatology by Chayanupatkul and coworkers1 who found that fewer than 10% of HCC cases in CHB patients developed in the absence of cirrhosis in the U.S.A. The main risk factors for this entity were African American and Asian race, a family history of HCC and hypertension. Therefore, the study by Chayanupatkul et al. suggests that in the absence of cirrhosis, HCC surveillance should be considered for African American and Asian patients if they are older than 40 and have a family history of HCC or are hypertensive.

    Date de mise en ligne : Mardi 20 juin 2017
    Fred Poordad, David R. Nelson, Jordan J. Feld, Michael W. Fried, Heiner Wedemeyer, Lois Larsen, Daniel E. Cohen, Eric Cohen, Niloufar Mobashery, Fernando Tatsch, Graham R. Foster
    Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis
    Chronic hepatitis C virus (HCV) infection is characterized by progressive liver damage and fibrosis, which can lead to liver failure or hepatocellular carcinoma.1 In 2013, an estimated 357,800 people worldwide died from HCV-related cirrhosis, and an additional 342,500 people died from liver cancer caused by HCV.2 The burden of HCV-associated liver disease is projected to continue to increase in many countries in the coming decades.3

    Date de mise en ligne : Mardi 20 juin 2017
    Christophe Bureau, Danielle Adebayo, Mael Chalret de Rieu, Laure Elkrief, Dominique Valla, Markus Peck-Radosavljevic, Anne McCune, Victor Vargas, Macarena Simon-Talero, Juan Cordoba, Paolo Angeli, Silvia Rosi, Stewart MacDonald, Massimo Malago, Maria Stepanova, Zobair M. Younossi, Claudia Trepte, Randall Watson, Oleg Borisenko, Sun Sun, Neil Inhaber, Rajiv Jalan
    Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study
    Accumulation of ascites is a common complication of cirrhosis and one of the leading reasons for hospital admission.1 Approximately 60% of patients with cirrhosis develop ascites within 10years of diagnosis. Treatment of ascites includes restriction of dietary sodium and diuretics.2 However, some patients develop diuretic-resistant or intractable ascites, because of diuretic-induced complications such as renal dysfunction, hyponatremia or hepatic encephalopathy (HE).3,4

    Date de mise en ligne : Mardi 20 juin 2017
    Florent Artru, Alexandre Louvet, Isaac Ruiz, Eric Levesque, Julien Labreuche, Jose Ursic-Bedoya, Guillaume Lassailly, Sebastien Dharancy, Emmanuel Boleslawski, Gilles Lebuffe, Eric Kipnis, Philippe Ichai, Audrey Coilly, Eleonora De Martin, Teresa Maria Antonini, Eric Vibert, Samir Jaber, Astrid Herrerro, Didier Samuel, Alain Duhamel, Georges-Philippe Pageaux, Philippe Mathurin, Faouzi Saliba
    Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3
    Most countries have adopted the policy of allocating livers to the most severely ill patients when selecting candidates for liver transplantation (LT) with decompensated cirrhosis. This involves providing grafts to patients with the most advanced liver disease. Indeed, these patients are at the greatest risk of dying on the waiting list and therefore benefit most from LT, confirmed by a hazard ratio for mortality that decreases along with the severity of liver failure.1 End-stage cirrhosis is associated with the failure of other organs (renal insufficiency, encephalopathy, coagulopathy etc.).

    Date de mise en ligne : Mardi 20 juin 2017
    Maria J. Guillen-Sacoto, Ariel F. Martinez, Yu Abe, Paul Kruszka, Karin Weiss, Joshua L. Everson, Ramon Bataller, David E. Kleiner, Jerrold M. Ward, Kathleen K. Sulik, Robert J. Lipinski, Benjamin D. Solomon, Maximilian Muenke
    Human germline hedgehog pathway mutations predispose to fatty liver
    Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease in the United States, affecting 20–30% of adults and 7.6% of children.1 The severity of NAFLD ranges from simple steatosis (fat deposition without inflammation) to non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC).2,3 Although NAFLD is usually associated with obesity, type-2 diabetes, and hyperlipidemia4—resulting primarily from a high intake of foods rich in sugar and saturated fats (e.g.

    Date de mise en ligne : Mardi 20 juin 2017
    Sanchari Roy, Heike Bantel, Franziska Wandrer, Anne Theres Schneider, Jeremie Gautheron, Mihael Vucur, Frank Tacke, Christian Trautwein, Tom Luedde, Christoph Roderburg
    miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib
    Acute liver failure (ALF) represents a life-threatening condition associated with high morbidity and mortality. In ALF, liver cell death normally induces compensatory cell proliferation to restore liver mass and avoid loss of organ function.1,2 While the balance of liver regeneration and hepatocyte death plays a critical role in the outcome of ALF,3,4 the underlying regulatory mechanisms linking cell death with compensatory proliferation are still only poorly understood.

    Date de mise en ligne : Lundi 19 juin 2017
    Jian-Gao Fan, Seung-Up Kim, Vincent Wai-Sun Wong
    New trends on obesity and NAFLD in Asia
    Traditionally, obesity and its related diseases have been considered a problem in Western countries. However, in the past two decades, urbanisation in many Asian countries has led to a sedentary lifestyle and overnutrition, setting the stage for the epidemic of obesity. This article reviews the epidemiological trend of obesity in Asia, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD). Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries.

    Date de mise en ligne : Dimanche 18 juin 2017
    Paola Bertuccio, Federica Turati, Greta Carioli, Teresa Rodriguez, Carlo La Vecchia, Matteo Malvezzi, Eva Negri
    Reply to: “How to predict global trends in HCC mortality if neglect more than half the world’s cases?”
    We thank Dr. Sun for their interest in our work, and agree that China is the “great country of liver cancer”, a major site showing upward trends in several areas of the world.1 We also agree that it is difficult to predict trends in hepatocellular carcinoma (HCC) mortality in China, given the different evolving trends of its main risk factors, i.e. hepatitis B and C, non-alcoholic fatty liver disease, diabetes and alcohol use.2 We also appreciate the additional data they provided on liver cancer in China.

    Date de mise en ligne : Dimanche 18 juin 2017
    Qing Pang, Hui-Chun Liu, Lei Zhou, Hao Jin
    Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients
    Recently, Chayanupatkul and colleagues compared the demographic and clinical characteristics between cirrhotic and non-cirrhotic subgroups in patients with hepatitis B-related hepatocellular carcinoma (HCC).1 The authors concluded that race and HCC family history were the main risk factors for HCC in the absence of cirrhosis. In this study, hepatic cirrhosis was identified by Fibrosis-4 (FIB-4) score (with a cut-off value of 3.25) in partial HCC patients. As mentioned by Chayanupatkul et al.1 FIB-4 has a superior diagnostic performance for the detection of liver cirrhosis in patients with chronic hepatitis B (CHB).

    Date de mise en ligne : Dimanche 18 juin 2017
    Maneerat Chayanupatkul, Fasiha Kanwal
    Reply to: “Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection”
    We would like to thank Dr. Xiang and colleagues for their inquiries regarding our recently published article on hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) in the absence of cirrhosis. Our responses are as follows.

    Date de mise en ligne : Dimanche 18 juin 2017
    Maneerat Chayanupatkul, Fasiha Kanwal
    Reply to: “Inappropriate use of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients”
    We would like to thank Dr. Pang and colleagues for their comments on the limitation of using FIB-4 in determining cirrhosis in patients with hepatocellular carcinoma (HCC).

    Date de mise en ligne : Mercredi 14 juin 2017
    Simone Susser, Julia Dietz, Bernhard Schlevogt, Eli Zuckerman, Mira Barak, Valeria Piazzolla, Anita Howe, Holger Hinrichsen, Sandra Passmann, Rasha Daniel, Markus Cornberg, Alessandra Mangia, Stefan Zeuzem, Christoph Sarrazin
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras
    A global pathogen, the hepatitis C virus (HCV) leads to severe liver damage in chronically infected patients. Development of cirrhosis, hepatocellular carcinoma, liver failure and finally death are all associated with chronic HCV infection.1 A recent study estimated a global prevalence of chronic HCV infection of 80 (64–103) million people,2 of which approximately 500,000 die each year from HCV-related liver diseases.3

    Date de mise en ligne : Mardi 13 juin 2017
    Li-Yang Sun, Han Zhang, Zhen-Li Li, Chao Li, Ming-Da Wang, Tian Yang
    How to predict global trends in HCC mortality if neglecting more than half the world’s cases?
    We read with great interest the article by Bertuccio et al.,1 and appreciate their meaningful work. Using the World Health Organization database on death certification, this study analyzed the data for hepatocellular carcinoma (HCC) over the period of 1990–2014. Sixteen European, five American countries, and six other countries worldwide were included, as well as the European Union (EU) as a whole. The authors claimed that their study has updated the worldwide trends for HCC mortality and made predictions for the trends of 2020.

    Date de mise en ligne : Mardi 13 juin 2017
    Hiroko Nagata, Mina Nakagawa, Yasuhiro Asahina, Ayako Sato, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Shun Kaneko, Satoshi Otani, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Toshihiko Nouchi, Hideki Sakai, Makoto Tomita, Mamoru Watanabe, Ochanomizu Liver Conference Study Group
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C
    Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death in the world[1]. Viral eradication after interferon (IFN)-based therapy has been associated with a reduced risk of developing HCC[2,3] in chronic hepatitis C (CHC) patients. With the development of potent direct-acting antiviral agent (DDA) combinations, an over 90% sustained virological response (SVR) was achieved, even in patients with a high risk for the development of HCC such as those who are elderly or have severe fibrosis[4].

    Date de mise en ligne : Mercredi 07 juin 2017
    Giulia Dondi, Giulia Lancellotti, Marco Bertolotti, Chiara Mussi
    The relationship between age and fat infiltration in liver and muscle
    We read with great interest the paper by Koo et al. in the January issue of the Journal of Hepatology.1

    Date de mise en ligne : Mercredi 07 juin 2017
    Thomas Reiberger, Mattias Mandorfer
    Reply to: “Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?”
    We want to thank Dr. Kalambokis and colleagues for their letter commenting on some interesting aspects of our recent Grand Rounds article on the use of non-selective betablockers (NSBBs) in patients with decompensated cirrhosis published in the Journal of Hepatology.1

    Date de mise en ligne : Mardi 06 juin 2017
    Marion Duriez, Yassmina Mandouri, Bouchra Lekbaby, Hualin Wang, Aurélie Schnuriger, Francois Redelsperger, Chiara Ida Guerrera, Marine Lefevre, Veronique Fauveau, James Ahodantin, Ivan Quetier, Cerina Chhuon, Samir Gourari, Alexandre Boissonnas, Upkar Gill, Patrick Kennedy, Nabil Debzi, Delphine Sitterlin, Mala K. Maini, Dina Kremsdorf, Patrick Soussan
    Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity
    Constitutive splicing is an essential step for eukaryotic gene expression, generating mature mRNAs by removing introns and allowing exons to be joined together accurately. In contrast, alternate splicing (including exon skipping, intron retention, alternate 3′ or 5′ splice sites) contributes to the diversity of the eukaryotic proteome1 and controls the expression of regulatory proteins in the viral context.2 The splicing process is coordinated by the spliceosome, a large ribonucleoprotein complex.

    Date de mise en ligne : Mardi 06 juin 2017
    Georgios N. Kalambokis, Gerasimos Baltayannis, Dimitrios Christodoulou, Leonidas Christou
    Beta adrenergic blockade and advanced cirrhosis: Does it really improve survival in patients with acute-on-chronic liver failure?
    We read with great interest the article by Thomas Reiberger and Mattias Mandorfer on the optimal use of non-selective beta-blockers (NSBBs) in patients with advanced cirrhosis.1 The safety of NSBBs in end-stage cirrhosis has been an issue of intense debate in recent years, due to the associated reduction in cardiac reserve.1 The positive impact of NSBBs on overall survival was reported by prospective studies, including studies in highly selected patient populations with less severe cirrhosis and short-term follow-up in the context of clinical trials,2 or in the setting of a transplant wait-list.

    Date de mise en ligne : Lundi 05 juin 2017
    Xiufang Weng, Ying He, Lavanya Visvabharathy, Chia-Min Liao, Xiaosheng Tan, Arjun Balakumar, Chyung-Ru Wang
    Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease
    The liver is constantly exposed to large varieties of antigens derived from the gastrointestinal tract and from systemic circulation, a possible explanation for why liver tissue is subject to a greater degree of immune tolerance than some other organs.1 Despite this, disruption of tolerance leads to inflammatory liver injuries during chronic diseases, such as persistent viral infection,2 drug toxicity3 and autoimmune hepatitis (AIH).4 As one of the predominant lymphocyte populations in the liver, CD1d-restricted natural killer T (NKT) cells contribute to the maintenance of immune tolerance, but also direct adverse immune responses in the liver.

    Date de mise en ligne : Lundi 05 juin 2017
    Emily S. Wires, Kathleen A. Trychta, Susanne Bäck, Agnieszka Sulima, Kenner C. Rice, Brandon K. Harvey
    High fat diet disrupts endoplasmic reticulum calcium homeostasis in the rat liver
    Metabolic disorders have plagued developing countries in the past century. Excessive nutrient intake, sedentary lifestyles, and increased food availability have all contributed to disease progression. According to the World Health Organization, in 2014 approximately 1.9billion adults were overweight, with 600 million estimated to be obese.1 Aside from comorbidities such as cardiovascular disease and type 2 diabetes often associated with obesity, the effects are also seen on a cellular level. Hepatocytes in particular, are among the cells most affected by obesity.

    Date de mise en ligne : Lundi 05 juin 2017
    Peng-Fei Ma, Chun-Chen Gao, Jing Yi, Jun-Long Zhao, Shi-Qian Liang, Yang Zhao, Yu-Chen Ye, Jian Bai, Qi-Jun Zheng, Ke-Feng Dou, Hua Han, Hong-Yan Qin
    Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice
    Liver fibrosis caused by various etiologies is a common pathological process of end-stage liver diseases. Advanced fibrosis leads to cirrhosis, liver failure, hepatocarcinoma and ultimately death.1 Liver transplantation, the only effective treatment for end-stage liver diseases, is limited by the shortage of available donors. Therefore, alternative therapies for fibrosis/cirrhosis including antiviral therapy, hepatic stellate cells (HSCs)-targeted therapy, and cytotherapy are under intensive development.

    Date de mise en ligne : Vendredi 26 mai 2017
    Luiz Eduardo Baggio Savio, Paola de Andrade Mello, Vanessa R. Figliuolo, Thiago F. de Avelar Almeida, Patrícia T. Santana, Suellen D.S. Oliveira, Claudia L.M. Silva, Linda Feldbrügge, Eva Csizmadia, Richard D. Minshall, Maria Serena Longhi, Yan Wu, Simon C. Robson, Robson Coutinho-Silva
    CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury
    Sepsis is a leading cause of death in intensive care units worldwide1 and represents a major public health issue due to high numbers of deaths of economically productive people and major morbidity in survivors. Aspects of the associated morbidity and mortality are related to onset of shock and hemodynamic compromise with multiple organ system dysfunction and failure due to the excessive, unfettered inflammation.1,2

    Date de mise en ligne : Vendredi 26 mai 2017
    Toshiaki Teratani, Kengo Tomita, Takahiro Suzuki, Hirotaka Furuhashi, Rie Irie, Shigeaki Hida, Yoshikiyo Okada, Chie Kurihara, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Hidetsugu Saito, Toshifumi Hibi, Soichiro Miura, Ryota Hokari, Takanori Kanai
    Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity via TLR9 signaling
    Acetaminophen (N-acetyl-para-aminophenol [APAP]) is one of the most widely used drugs worldwide owing to its applications in managing pain and hyperthermia; however, APAP can induce liver injury. Consequently, APAP-induced liver injury is the most frequent cause of acute liver failure in the USA and elucidation of the pathological mechanisms of this condition are critical.1

    Date de mise en ligne : Mardi 23 mai 2017
    Zhen Lu, Bingfeng Zuo, Renwei Jing, Xianjun Gao, Quan Rao, Zhili Liu, Han Qi, Hongxing Guo, HaiFang Yin
    Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models
    Hepatocellular carcinoma (HCC) presents as one of the most lethal malignancies worldwide owing to its aggressive nature, high mortality and low response rates to treatments in the clinic.1 A multitude of therapeutic approaches are under intensive investigation. Among them, chemotherapeutic and radiotherapeutic interventions have been extensively used, however the survival benefit is limited.2 Resection surgery is effective for early-stage HCC patients, but is only amenable to a subpopulation of patients and HCC frequently recurs.

    Date de mise en ligne : Lundi 22 mai 2017
    Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell
    Treatment of NAFLD with diet, physical activity and exercise
    Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases (NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also regress liver disease. Weight reductions of ⩾10% can induce a near universal non-alcoholic steatohepatitis resolution and fibrosis improvement by at least one stage. However, modest weight loss (>5%) can also produce important benefits on the components of the NAFLD activity score (NAS). Additionally, we need to explore the role of total calories and type of weight loss diet, micro- and macronutrients, evidence-based benefits of physical activity and exercise and finally support these modifications through established behavioural change models and techniques for long-term maintenance of lifestyle modifications.

    Date de mise en ligne : Vendredi 19 mai 2017
    Lai Wei, David Kung-Chun Chiu, Felice Ho-Ching Tsang, Cheuk-Ting Law, Carol Lai-Hung Cheng, Sandy Leung-Kuen Au, Joyce Man-Fong Lee, Carmen Chak-Lui Wong, Irene Oi-Lin Ng, Chun-Ming Wong
    Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3
    Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide.1 In 2012, there were 782,000 new HCC cases diagnosed, and 746,000 patients died of HCC. HCC accounts for 9.1% of all cancer deaths, making it the second largest cause of cancer mortality worldwide.1,2 The patient survival rate of HCC is extremely poor. This is mainly due to the asymptomatic progression of HCC at the early stage and high metastasis potential at the late stage. Conventional chemotherapies have no significant impact on the overall survival, and only a small fraction of HCC patients are eligible for curative surgical resection.

    Date de mise en ligne : Vendredi 19 mai 2017
    Julien Calderaro, Gabrielle Couchy, Sandrine Imbeaud, Giuliana Amaddeo, Eric Letouzé, Jean-Frédéric Blanc, Christophe Laurent, Yacine Hajji, Daniel Azoulay, Paulette Bioulac-Sage, Jean-Charles Nault, Jessica Zucman-Rossi
    Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
    Malignant primary liver tumours are the second leading cause of cancer-related death worldwide, with an increasing incidence in almost all countries.1 They are mainly represented by hepatocellular carcinoma (HCC) that results from the malignant transformation of hepatocytes. The most frequent risk factors of HCC comprise of alcohol intake, infection by hepatitis B (HBV) or hepatitis C (HCV) viruses, and metabolic syndrome.2 Although surveillance protocols of patients at-risk to develop HCC have significantly improved, clinical outcome remains poor with a majority of patients presenting with advanced disease not eligible for curative therapy.

    Date de mise en ligne : Jeudi 18 mai 2017
    Thomas Pembroke, Marc Deschenes, Bertrand Lebouché, Amine Benmassaoud, Maida Sewitch, Peter Ghali, Philip Wong, Alex Halme, Elise Vuille-Lessard, Costa Pexos, Marina B. Klein, Giada Sebastiani
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis
    Hepatic steatosis (HS) is an accumulation of fat in the liver, which may eventually progress to steatohepatitis, a pathologic inflammatory response leading to fibrosis, cirrhosis and liver failure.1 HS is particularly common in hepatitis C virus (HCV)-infected patients with human immunodeficiency virus (HIV) co-infection, with reported frequencies ranging between 30 and 70%.2–6 HCV may induce HS through several mechanisms, including altered lipid metabolism, metabolic risk factors in non-genotype 3 infections and a direct steatogenic effect of HCV genotype 3.

    Date de mise en ligne : Jeudi 18 mai 2017
    Lester Suárez-Amarán, Carla Usai, Marianna Di Scala, Cristina Godoy, Yi Ni, Mirja Hommel, Laura Palomo, Víctor Segura, Cristina Olagüe, Africa Vales, Alicia Ruiz-Ripa, Maria Buti, Eduardo Salido, Jesús Prieto, Stephan Urban, Francisco Rodríguez-Frias, Rafael Aldabe, Gloria González-Aseguinolaza
    A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction
    Hepatitis delta virus (HDV), the only member of the genus Deltavirus, is a defective RNA virus that requires the surface antigens of hepatitis B virus (HBV) (HBsAg) for viral assembly and transmission, and that dictates hepatocyte tropism.1,2 HBV/HDV co-infection is more frequently associated with severe or fulminant hepatitis, higher risk of cirrhosis and decompensated liver disease, and higher mortality than HBV mono-infection.3–7

    Date de mise en ligne : Mercredi 17 mai 2017
    Marina Ruiz de Galarreta, Amaia Lujambio
    Therapeutic editing of hepatocyte genome in vivo
    The recent development of gene editing platforms enables making precise changes in the genome of eukaryotic cells. Programmable nucleases, such as meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)-associated nucleases have revolutionized the way research is conducted as they facilitate the rapid production of mutant or knockout cellular and animal models. These same genetic tools can potentially be applied to cure or alleviate a variety of diseases, including genetic diseases that lack an efficient therapy.

    Date de mise en ligne : Mardi 16 mai 2017
    Reiner Wiest, Agustin Albillos, Michael Trauner, Jasmohan S. Bajaj, Rajiv Jalan
    Targeting the gut-liver axis in liver disease
    The gut-liver axis is widely implicated in the pathogenesis of liver diseases, where it is increasingly the focus of clinical research. Recent studies trialling an array of therapeutic and preventative strategies have yielded promising results. Considering these strategies, the armamentarium for targeting the gut-liver axis will continue to expand. Further clinical trials, translated from our current knowledge of the gut-liver axis, promise an exciting future in liver treatment.

    Date de mise en ligne : Vendredi 21 avril 2017
    Naoki Kawagishi, Goki Suda, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection
    The worldwide use of interferon (IFN)-free direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection has raised concerns regarding hepatitis B virus (HBV) reactivation after HCV clearance. In patients with HCV and HBV co-infection, HBV-reactivation has been reported during or after IFN-based anti-HCV treatment. Because HCV is thought to suppress HBV replication,1 therapeutic eradication of HCV may increase HBV replication, resulting in HBV-reactivation. Until recently, the standard therapy for chronic HCV infection was IFN-based therapy.

    Date de mise en ligne : Lundi 18 fvrier 2013
    Shunji Nagai, Marcelo Facciuto, Shozo Mori, Mizuki Ninomiya, Juan P. Rocca, Alan Contreras-Saldivar, Myron E. Schwartz, Sander S. Florman
    WITHDRAWN: Recurrence prediction of hepatocellular carcinoma after liver transplantation by ischemia time and tumor characteristics
    This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

    Date de mise en ligne : Jeudi 01 janvier 1970
    EASL summit: HCC summit, Geneva, Switzerland, 2018

    Date de mise en ligne : Jeudi 01 janvier 1970
    Thierry Gustot, Banwari Agarwal
    Selected patients with acute-on-chronic liver failure grade 3 are not too sick to be considered for liver transplantation
    The severe form of acute decompensation of cirrhosis accompanied by organ failure, is now more precisely recognized as acute-on-chronic liver failure (ACLF) syndrome, characterized by organ/system failures, defined by the chronic liver failure (CLIF)-sequential organ failure assessment (SOFA) score, and a 28-day mortality rate of at least 15% in a patient with an acute decompensation of cirrhosis.1 Short- and mid-term prognoses of this syndrome are highly correlated to the number of organ failures (OFs), determining the grade of ACLF (from 1 [one OF] to 3 [three or more OFs]).

    Date de mise en ligne : Jeudi 01 janvier 1970
    EASL: Join the community and benefit from reduced fees to ILC 2018

    Date de mise en ligne : Jeudi 01 janvier 1970

    Date de mise en ligne : Jeudi 01 janvier 1970
    EASL monothematic conference: Striving towards the elimination of HCV infection, Berlin, Germany, 2018

    Date de mise en ligne : Jeudi 01 janvier 1970
    EASL funding: fellowships and mentorships

    Date de mise en ligne : Jeudi 01 janvier 1970
    EASL school of hepatology: Metabolism, immunity and liver disease, Munich, Germany, 2018

    Date de mise en ligne : Jeudi 01 janvier 1970
    The International Liver CongressTM, Paris, France, 2018

    Date de mise en ligne : Jeudi 01 janvier 1970
    Editorial Board

    Date de mise en ligne : Jeudi 01 janvier 1970
    Richard Moreau, Ramon Bataller, Thomas Berg, Jessica Zucman-Rossi, Rajiv Jalan
    From the Editor’s desk...
    Acute on chronic liver failure (ACLF) is a newly defined entity that complicates the course of relatively well patients with chronic liver disease. Depending upon its severity, ACLF is associated with 28-day mortality rates ranging from about 15% to over 80%. Treatment options for this condition are limited to supportive medical care and the role of transplantation is unknown. Louvet et al. report the results of a multicenter study assessing the outcomes of patients transplanted for severe ACLF (Grade 3) performed in France.